Article Text

other Versions

PDF
Randomised controlled trial
Montelukast potentially efficacious in children with non-severe obstructive sleep apnoea in the short term
  1. Joanna E MacLean
  1. Department of Pediatrics, University of Alberta, Edmonton, Canada
  1. Correspondence to : Joanna E MacLean
    Department of Pediatrics, University of Alberta, 4–590 Edmonton Clinic Health Academy, 11415 87th Avenue NW, Edmonton, Alberta, Canada T6G 1C9; joanna.maclean{at}ualberta.ca

Statistics from Altmetric.com

Commentary on: Goldbart AD, Greenberg-Dotan S, Tal A. Montelukast for children with obstructive sleep apnea: a double-blind, placebo-controlled study. Pediatrics 2012;130:e575–80.

Context

Obstructive sleep apnoea (OSA) is a common condition affecting 1–5% of children. The most common cause of OSA in childhood is adenotonsillar hypertrophy which is mediated by inflammation. While anti-inflammatory therapy is commonly trialled as a treatment strategy in mild forms, there is a paucity of literature to support this treatment strategy for children with OSA.

Methods

This study by Goldbart and colleagues was conducted in a single tertiary care centre in a metropolitan area. This is a double-blind randomised placebo-controlled trial of montelukast for the treatment of non-severe OSA in children. The population for recruitment was children referred for evaluation of snoring. Subjects were 2–10 years of age, had habitual snoring, non-severe OSA (defined as an apnoea/hypopnoea index <10 events/h) and were naïve to montelukast therapy as well as adenotonsillectomy. Children were excluded if they …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.